A Novel Nomogram for Peritoneal Mesothelioma Predicts Survival

被引：0
作者：
Nicholas P. Schaub
Meghna Alimchandani
Martha Quezado
Phil Kalina
John S. Eberhardt
Marybeth S. Hughes
Tatiana Beresnev
Raffit Hassan
David L. Bartlett
Steven K. Libutti
James F. Pingpank
Richard E. Royal
Udai S. Kammula
Prakash Pandalai
Giao Q. Phan
Alexander Stojadinovic
Udo Rudloff
H. Richard Alexander
Itzhak Avital
机构：
[1] National Cancer Institute/NIH,GI and Hepatobiliary Malignancies Section, Surgery Branch
[2] National Cancer Institute/NIH,Laboratory of Pathology
[3] National Cancer Institute/NIH,Solid Tumor Immunotherapy Section, Laboratory of Molecular Biology
[4] DecisionQ Corporation,Division of Surgical Oncology
[5] University of Pittsburgh Medical Center,Department of Surgery
[6] Montefiore Medical Center/Albert Einstein College of Medicine,Department of Surgical Oncology
[7] The University of Texas MD Anderson Cancer Center,Department of Surgery, Division of Surgical Oncology
[8] Walter Reed National Military Medical Center,Division of Surgical Oncology, Department of Surgery and the Marlene and Stewart Greenebaum Cancer Center
[9] University of Maryland School of Medicine,undefined
[10] Bon Secours Cancer Institute,undefined
来源：
Annals of Surgical Oncology | 2013年 / 20卷
关键词：
Overall Survival; Bayesian Belief Network; Malignant Peritoneal Mesothelioma; Early Postoperative Intraperitoneal Chemotherapy; Peritoneal Carcinomatosis Index;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：555 / 561
页数：6
相关论文
共 87 条
[1]  
Yan TD(2007)Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma Ann Surg Oncol. 14 41-49
[2]  
Brun EA(2003)Clinical presentation of peritoneal mesothelioma Tumori. 89 269-273
[3]  
Cerruto CA(2007)Clinical results of cytoreduction and HIPEC for malignant peritoneal mesothelioma Cancer Treat Res. 134 343-355
[4]  
Haveric N(1980)Current concepts: malignant mesothelioma N Engl J Med. 303 200-202
[5]  
Chang D(1985)Early peritoneal mesothelioma: a treatable malignancy Lancet. 2 977-981
[6]  
Sugarbaker PH(1999)Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma J Surg Oncol. 70 6-12
[7]  
Acherman YI(1999)Management of peritoneal-surface malignancy: the surgeon’s role Langenbecks Arch Surg. 384 576-587
[8]  
Welch LS(2003)The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies Surg Oncol Clin N Am. 12 673-688
[9]  
Bromley CM(2003)Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents Surg Oncol Clin N Am. 12 689-701
[10]  
Sugarbaker PH(2003)Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy J Clin Oncol. 21 4560-4567
123456789